Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy--implications for a pathologist
- PMID: 17760666
- DOI: 10.1111/j.1524-4741.2007.00465.x
Changes in the tumor grade and biological markers in locally advanced breast cancer after chemotherapy--implications for a pathologist
Abstract
There is insurgence of literature evaluating prognostic and predictive factors in breast carcinomas treated with chemotherapy, with a parallel need to develop guidelines for the pathologist interpreting such excisions. Prechemotherapy gun biopsy and postchemotherapy excision specimens from 78 women with locally advanced breast cancer were analyzed for histological changes in the tumor, changes in the tumor grade, hormone receptors, cerb2, and bcl2 and their impact on disease-free survival (DFS). An unusually prominent granulomatous response to tumor was seen in three cases. The tumor grade changed in five patients, estrogen receptor (ER) expression was altered in 10 cases, progesterone receptor detection changed in 16 cases, cerb2 in one case and bcl2 in 16 cases. Fixation of the gun biopsy in Bouin's fluid and severe damage of nuclei after chemotherapy were the reasons for shift in the expression of hormone receptors. A low-grade tumor was associated with better response to chemotherapy. In the Kaplan-Meier analysis the ER expression and a low-grade tumor (grade I and II) significantly affected DFS. None of the factors evaluated impacted the overall survival of patients. To conclude there is a change in the tumor grade, bcl2, cerb2 and hormone receptors after chemotherapy. A pathologist interpreting specimens of breast cancer after chemotherapy must always record the postchemotherapy grade as it is an indicator of better response to chemotherapy and survival.
Similar articles
-
Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?J Surg Res. 2001 Aug;99(2):161-8. doi: 10.1006/jsre.2001.6084. J Surg Res. 2001. PMID: 11469882
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.J Natl Cancer Inst. 2008 Jun 4;100(11):805-14. doi: 10.1093/jnci/djn151. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505968 Clinical Trial.
-
Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.Cancer Invest. 2008 Aug;26(7):671-9. doi: 10.1080/07357900801891628. Cancer Invest. 2008. PMID: 18608215 Clinical Trial.
-
alphaB-crystallin is a novel predictor of resistance to neoadjuvant chemotherapy in breast cancer.Breast Cancer Res Treat. 2008 Oct;111(3):411-7. doi: 10.1007/s10549-007-9796-0. Epub 2007 Oct 30. Breast Cancer Res Treat. 2008. PMID: 17968656
-
Potential use of image analysis for the evaluation of cellular predicting factors for therapeutic response in breast cancers.Anal Quant Cytol Histol. 1997 Aug;19(4):316-28. Anal Quant Cytol Histol. 1997. PMID: 9267565 Review.
Cited by
-
Effect of Neoadjuvant Chemotherapy on Immunohistochemistry in Breast Cancer.Cureus. 2025 Jul 9;17(7):e87579. doi: 10.7759/cureus.87579. eCollection 2025 Jul. Cureus. 2025. PMID: 40786273 Free PMC article.
-
Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.Medicine (Baltimore). 2017 Dec;96(51):e9384. doi: 10.1097/MD.0000000000009384. Medicine (Baltimore). 2017. PMID: 29390540 Free PMC article. Review.
-
Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent?Case Rep Gastrointest Med. 2015;2015:132030. doi: 10.1155/2015/132030. Epub 2015 Mar 29. Case Rep Gastrointest Med. 2015. PMID: 25893119 Free PMC article.
-
Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer.Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820928435. doi: 10.1177/1533033820928435. Technol Cancer Res Treat. 2020. PMID: 32508292 Free PMC article.
-
Prognostic value of hormone receptor status conversion following neoadjuvant chemotherapy in a series of operable breast cancer patients.Int J Clin Exp Pathol. 2014 Jun 15;7(7):4086-94. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25120787 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials